Engflag

Bioglobin

Quick links to important sections

Bioglobin

Bioglobin_ES

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Bioglobin

What is Bioglobin?

Bioglobin is a therapeutic preparation consisting of human normal immunoglobulin (IVIg). It is a highly purified solution of antibodies, specifically immunoglobulin G (IgG), which is extracted from the pooled plasma of a large number of donors. These antibodies are essential components of the immune system that help the body recognize and neutralize various foreign substances, such as bacteria and viruses.

Composition and Mechanism

The primary active component of Bioglobin is human protein, with a broad spectrum of antibodies against various infectious agents. The distribution of IgG subclasses in the preparation is closely similar to that found in natural human plasma.

Bioglobin works through two primary mechanisms depending on the underlying condition:

  • Replacement Therapy: In individuals who have a deficiency in their own antibody production, Bioglobin provides the necessary IgG levels to help maintain a functional immune defense, thereby reducing the risk of infections.
  • Immunomodulation: In certain autoimmune or inflammatory conditions, the administration of high doses of immunoglobulins can help regulate an overactive or malfunctioning immune system. It interacts with various immune cells and signaling molecules to help restore balance.

Therapeutic Application

Bioglobin is utilized in a variety of clinical contexts where the immune system requires support or regulation. This includes primary immunodeficiency syndromes where antibody production is absent or severely impaired, as well as secondary immunodeficiencies in patients who have lost the ability to produce sufficient antibodies due to other medical conditions.

Beyond replacement, it is used in the management of specific disorders characterized by an immune-mediated attack on the body's own tissues, such as certain types of thrombocytopenia or inflammatory neurological conditions. By providing a diverse pool of healthy antibodies, the preparation helps stabilize the patient's immune response.

Regulatory References

  1. NIH MedlinePlus on Immunoglobulins
  2. NIH MedlinePlus on Immunoglobulins and Passive Immunity

What side effects are possible with Bioglobin?

Possible side effects and safety information

The safety profile for Human Normal Immune Globulin (Bioglobin) is formally classified by regulatory authorities based on the frequency and type of documented adverse reactions. These effects are grouped into System-Organ Classes (SOCs) to define the specific body systems potentially affected.

Frequency-Classified Adverse Reactions

Adverse reactions are formally ranked in regulatory texts:

  • Very Common reactions (occurring in ge 1 in 10 people) typically include headache, various types of pain (including back and extremity pain), and pyrexia (fever).
  • Common reactions (occurring in ge 1 in 100 people) often involve nausea, vomiting, fatigue, dizziness, hypotension (low blood pressure), and myalgia (muscle pain).

Serious Adverse Reactions and Safety Considerations

Regulatory documents highlight rare but clinically significant adverse reactions, which may affect the Nervous System (e.g., Aseptic Meningitis Syndrome), Vascular System (e.g., Thromboembolic events or blood clots), and Renal System (e.g., Acute Renal Failure). Severe, immediate systemic reactions such as Anaphylactic Shock are also documented.

Safety constraints exist for specific populations. Patients with pre-existing renal impairment or advanced age are noted to be at an increased risk of renal and thromboembolic events. Furthermore, the product is formally contraindicated in individuals with known severe selective IgA deficiency who have pre-existing anti-IgA antibodies, due to a heightened risk of severe hypersensitivity.

Common reactions like headache and fever are frequently observed during the infusion itself or within an hour following its completion, a time-related pattern noted in the official regulatory data.

Overdose and Emergency Response

Bioglobin Overdose and When to Seek Help

The official regulatory profile for Bioglobin, a Human Normal Immune Globulin, defines overdose risks based on the consequences of over-administration due to its high protein load and volume. Documented overdose presentations include Hypervolaemia (volume overload) and a resulting increase in Serum Viscosity.

Severe Manifestations and Outcomes

Regulatory documentation cites potential for severe, life-threatening outcomes, including Thromboembolic Events (e.g., stroke, myocardial infarction) linked to hyperviscosity, and Acute Renal Failure. Over-administration is also associated with symptoms of Aseptic Meningitis Syndrome.

Regulator-Mandated Actions

When signs of these severe complications manifest, official labeling requires patients to seek immediate medical attention. The primary procedural intervention documented is the reduction or cessation of the infusion, followed by symptomatic treatment. No specific antidote is listed in the regulatory documents for Bioglobin overdose; however, treatment for associated shock or acute complications must be implemented immediately.

Population Considerations

The risk of developing Acute Renal Failure or other severe outcomes is noted as increased in the elderly (over age 65) and in patients with established risk factors, such as pre-existing renal insufficiency or diabetes mellitus.

Therapeutic Uses of Bioglobin

What Bioglobin Treats: Main Uses and Benefits

Bioglobin is utilized in clinical contexts where additional symptomatic support is appropriate for managing certain serious conditions and their associated symptoms. Human Normal Immune Globulin (IVIG) is utilized for conditions falling into two primary therapeutic domains: immune replacement and immunomodulation.

Therapeutic Context and Benefit

The medication is applied across conditions presenting with systemic or functional discomfort, including inherited Primary Humoral Immunodeficiency (PI), certain autoimmune neuropathies (like CIDP and MMN), and specific immune-mediated blood disorders like Immune Thrombocytopenic Purpura (ITP). In cases of antibody deficiency, Bioglobin may assist as a prophylaxis to counter the symptom pattern of recurrent and severe bacterial infections.

For autoimmune conditions, it helps manage symptoms such as progressive muscle weakness or excessive bruising and high risk of bleeding. This support is aimed at assisting with maintaining functional stability and easing the overall symptom burden.

“Bioglobin therapy is used to provide supportive relief and assists with managing the high symptomatic risk associated with immune-related conditions.”

Quick Fact: Relief for Infection Vulnerability Bioglobin may assist with managing symptoms related to recurrent infection vulnerability for patients who are unable to produce adequate protective antibodies.

Regulatory References

  1. Intravenous Immunoglobulin (IVIG) - StatPearls - NIH

Eligibility and Restrictions for Use

Who Can and Cannot Use Bioglobin?

Eligibility for Bioglobin (Human Normal Immune Globulin) is strictly defined by regulatory documents, establishing absolute prohibitions and specific conditions for use.

Contraindicated Populations

Bioglobin must not be used in individuals with a history of severe systemic reactions or anaphylaxis to human immunoglobulin products. The medicine is also contraindicated for patients with Selective Immunoglobulin A (IgA) deficiency who have pre-formed antibodies against IgA, due to the high risk of a severe allergic response.

Age and Condition-Based Restrictions

Official labeling generally indicates Bioglobin use for children aged two years and older for certain conditions. While older adults (ge 65) are generally approved, they require close monitoring as they are considered a population with risk factors for renal or thrombotic events.

Use requires regulatory caution for individuals with pre-existing risk factors such as renal impairment, hypovolemia, or those prone to thrombotic events. Furthermore, Bioglobin use during pregnancy is not generally recommended unless clearly needed and is subject to official risk classification, which often advises caution.

What should I know about interactions with other medicines?

Bioglobin Interactions with other medicines and products

The official regulatory profile for Human Normal Immune Globulin establishes its interaction patterns based on immune response, pharmacokinetics, and physical compatibility. These documented interactions primarily involve specific vaccine types and agents that modify the body’s management of immunoglobulin.

Interaction Entity Interaction Type Regulatory Restriction or Outcome
Live Attenuated Virus Vaccines Pharmacodynamic Interference Co-administration requires a mandatory timing separation interval to ensure the passively transferred antibodies in Bioglobin do not impair the vaccine's ability to induce a protective immune response. The required delay is strictly dose-dependent and can extend for periods up to 11 months following Bioglobin administration.
FcRn-blocking agents (e.g., Rozanolixizumab) Exposure Modification These agents function by accelerating the breakdown of Immunoglobulin G (IgG). This interaction is officially documented to result in reduced Bioglobin plasma levels and a corresponding loss of the product's intended effectiveness due to increased clearance.

Other Documented Interactions and Constraints

The administration of Bioglobin may lead to misleading positive results in certain medical serological tests, including the Direct Antiglobulin Test (Coombs test), due to the transient presence of transferred antibodies. Additionally, specific formulations of Bioglobin have a documented physical or chemical incompatibility with heparin. Consequently, administration lines must be adequately flushed between sequential infusions of Bioglobin and heparin to prevent product degradation or physical complications. These label-based constraints structure the appropriate use alongside other medical products.

Mechanism of Action

Bioglobin, which contains Human Normal Immune Globulin ( HNIG), functions through a dual-action mechanism involving both the provision of functional antibodies and the modulation of immune cell activation.

The primary mechanism is Passive Replacement and Pathogen Neutralization. This process involves the direct supply of polyclonal Immunoglobulin G ( IgG) antibodies that bind to a vast array of pathogen-derived antigens. This binding triggers processes like neutralization and opsonization , and results in systemic clearance of microbial components and soluble toxins.

The second mechanism is Immune System Modulation and Effector Cell Control. This action is dose-dependent, where high concentrations of IgG interact with Fc Gamma Receptors ( Fcgamma Rs) on immune cells, promoting inhibitory signals within the cell. This engagement modulates the inflammatory cascade and leads to the downregulation of aberrant signaling pathways, which results in the modulation of T H cell activity and reduced inflammatory marker release.

Dosage and Administration Information

How Bioglobin Is Used: Administration Guidelines

Bioglobin (Human Normal Immune Globulin) is a liquid biologic product that is administered via two primary parenteral routes: Intravenous (IV) Infusion and Subcutaneous (SC) Infusion. The choice of route is dictated by the specific therapeutic setting, with IV infusion typically used for high-dose or acute administration and SC infusion reserved for flexible, long-term maintenance.

Dosing and Scheduling

Dosing is calculated based on milligrams per kilogram (mg/kg) of body weight. For replacement therapy, the standard IV maintenance dose ranges from 200 to 800 mg/kg and is typically administered every three to four weeks. For acute immunomodulatory uses, higher doses, such as 400 mg/kg/day for several days, are specified. The dosage and interval are subject to adjustment based on the patient's measured protective IgG trough level.

Administration Conditions

The preparation is provided as a ready-to-use aqueous solution and does not typically require dilution; mixing the product with other medications or intravenous solutions is generally prohibited. The solution must be clear to slightly opalescent before use.

All infusions must commence at a slow initial rate and be gradually increased only if the initial rate is well-tolerated. Clinical parameters establish a maximum infusion rate (e.g., up to 8 mg/kg/min for IVIg) that should not be exceeded. For SC administration, the use of an infusion pump across multiple injection sites may be specified.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Bioglobin

Bioglobin (Human Normal Immune Globulin) was studied for its use in several conditions where the body's natural immune response is deficient or imbalanced. The evidence landscape primarily includes Randomized Controlled Trials (RCTs), which are a complex type of study, along with systematic reviews, meta-analyses, and long-term observational research. Studies explored how symptoms change, how the body's protective proteins are maintained, and what outcomes relate to systemic or functional imbalance, according to official regulatory assessments.

Evidence for Antibody Replacement in Primary Immunodeficiency

The primary research for antibody replacement involves RCTs and long-term observational cohort studies. Research examined outcomes related to systemic or functional imbalance, such as the measurement of the Annualized Rate of Serious Bacterial Infections (ASBI), hospitalization frequency, and overall survival in the observed groups. Studies reported how Bioglobin administration was associated with the maintenance of IgG concentrations within target ranges. While research provides context on infection rates, most core efficacy studies focus on short-term (one-year) outcomes, and long-term effects are not fully established by initial RCTs.

Research Base for Immunomodulatory Uses in Neurological Conditions

For neurological conditions like Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), RCTs that compared Bioglobin to a placebo monitored outcomes reflecting daily functioning, focusing on measurement of changes in motor function and disability. Research highlights changes measured during the study period, and studies monitored how sustained functional assessment was associated with regular administration over time. Findings indicated how measured changes were observed in cohorts receiving plasma exchange. For Multifocal Motor Neuropathy (MMN), the research structure is similar but characterized by smaller-scale RCTs, and the overall evidence quality varies across studies for this specific indication.

Evidence for Managing Immune-Related Blood Disorders

Research for Immune Thrombocytopenic Purpura (ITP) primarily involves RCTs and Meta-analyses. Studies explored outcomes related to systemic or functional imbalance, such as the measurement of changes in platelet count and monitored the occurrence of acute bleeding events. Studies reported measured changes in the frequency of severe bleeding episodes in the acute setting among observed cohorts. However, the patterns of change in platelet count were often transient, and follow-up durations were limited (e.g., 2–4 weeks) for acute response assessment.

Key Studies & References Intravenous Immunoglobulin (IVIG) - StatPearls - NIH (Overview of Therapeutic Context)

Frequently Asked Questions (FAQ)

Common questions about Bioglobin (FAQ)

Q: What is the proper way to store this medication?

Official regulatory documents specify the exact conditions for storing Bioglobin. This usually includes a required temperature range and specific precautions to maintain the product's identity, strength, quality, and purity over time. Refer to the official product labeling for the specific storage instructions.

Q: Can I drink alcohol while taking this medicine?

The official product information provides specific warnings about consuming alcohol while using this medicine. Due to the potential for interactions or an increase in certain side effects, the labeling often advises caution or avoidance. The drug's official document contains specific guidance in its warnings section.

Q: Does this medicine make you sleepy?

Official labeling, such as the Summary of Product Characteristics (SmPC) or FDA label, lists central nervous system (CNS) effects among the drug's undesirable effects. These effects may include somnolence, which is the medical term for drowsiness. Due to these CNS effects, the official information includes relevant warnings concerning the operation of machinery or driving.

Q: Can children 2 years old use it?

The official labeling specifies the approved minimum age for use and provides dosing instructions only for those pediatric age groups for which the medicine has been tested and labeled. Information regarding eligible age groups, if any, is based on clinical evidence and is confirmed in the official regulatory documentation.

Q: What if I miss a dose?

The official Instructions for Use and Dosage and Administration sections of the product's regulatory documents provide directions for managing a missed dose. These instructions describe the steps that should be followed in the event a dose is missed.

How should Bioglobin be stored and disposed of?

How to Store and Dispose of Bioglobin

Official regulatory guidelines mandate specific conditions for the storage and disposal of Bioglobin to maintain its efficacy and safety.

Storage Requirements

Bioglobin must be stored at controlled room temperature, typically between 20 C and 25 C (68 F and 77 F). It is essential to keep the product in its original carton to protect it from light and excessive moisture. The medicine must not be frozen and should not be exposed to temperatures exceeding 30 C. Any reconstituted solution must be used within 8 hours and then discarded.

Disposal and Handling

To prevent accidental ingestion, always store Bioglobin out of the sight and reach of children. Unused or expired medication should be disposed of via an authorized drug take-back program. If a program is unavailable, follow official guidelines for safe household trash disposal. Do not flush Bioglobin down the toilet or pour it down a drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Bioglobin found in:

A-Z Index: